COEP Coeptis Therapeutics Inc.: Net earnings per one share for the last twelve months

The confirmed price history on the EPS (TTM) chart for Coeptis Therapeutics (COEP) is 50.00, driven by the implementation of automated bioreactors while maintaining medical oversight of tissue collection. The stability of these metrics is supported by strictly regulated air transport of raw materials via specialized services. The business relies on the development of cutting-edge NK-cell therapies for leukemia and myeloma, expanding partnerships with pharmaceutical behemoths.
COEP (Coeptis): analytical breakdowns and indicator data

The development of Coeptis Therapeutics (COEP) is based on academic alliances and molecule licensing, which makes profits dependent on R&D efficiency. This indicator measures the annual change in net earnings per share over 12 months, determining the stability of the financial trajectory regardless of trading volumes. By analyzing the percentage dynamics of EPS YoY TTM, an investor assesses the startup's margin of safety and the risk of a correction to the current trend.